In the second study, Probstel et al. performed a large, blinded study testing serum samples from 141 MS patients and 131 controls, with both a protein and a peptide ELISA, and failed to detect a significant difference between MS and control groups in KIR4.1 autoantibodies (Probstel et al., 2016). This evidence concerns the gene KCNJ10 and myeloid sarcoma.